Materias dentro de su búsqueda.
Mostrando 221 - 240 Resultados de 1,900 Para Buscar '"AstraZeneca"', tiempo de consulta: 0.20s Limitar resultados
  1. 221
    “…The AstraZeneca ChAdOx1 nCoV-19 (AZD1222) vaccine is associated with Thrombosis with Thrombocytopenia Syndrome (TTS) in 3/100,000 vaccinations with high fatality rates reported in many countries. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Thrombosis with Thrombocytopenia Syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination – A risk–benefit analysis for people < 60 years in Australia
  2. 222
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Real-world Effectiveness of the Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S Vaccines Against SARS-CoV-2 in Solid Organ and Islet Transplant Recipients
  3. 223
    “…All three vaccines, Pfizer-BioNTech, Oxford–AstraZeneca (ChAdOx1 CoV-19) and Moderna, cause post-vaccinal adverse effects; however, Moderna and Oxford–AstraZeneca (ChAdOx1) causes adverse effects more frequently than the Pfizer-BioNTech.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Adverse Effects of Pfizer (BioNTech), Oxford-AstraZeneca (ChAdOx1 CoV-19), and Moderna COVID-19 Vaccines among the Adult Population in Saudi Arabia: A Cross-Sectional Study
  4. 224
    “…We therefore aimed to estimate the effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines in preventing symptomatic and asymptomatic infection with respect to the Delta variant in a UK setting. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2
  5. 225
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Ischémie d’un membre et thrombose de l’artère pulmonaire après l’administration du vaccin ChAdOx1 nCoV-19 (Oxford–AstraZeneca) : un cas de thrombocytopénie thrombotique immunitaire induite par le vaccin
  6. 226
    Materias: “…Publication of this special issue was made possible by AstraZeneca.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Insights into foundational therapies for heart failure with reduced ejection fraction
  7. 227
    Materias: “…Publication of this special issue was made possible by AstraZeneca.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    New strategies and therapies for the prevention of heart failure in high‐risk patients
  8. 228
    por Talha, Khawaja M., Butler, Javed
    Publicado 2022
    Materias: “…Publication of this special issue was made possible by AstraZeneca.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Breakthroughs in the treatment of heart failure with mildly reduced and preserved ejection fraction
  9. 229
    Materias: “…Publication of this special issue was made possible by AstraZeneca.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Improving implementation of evidence‐based therapies for heart failure
  10. 230
    Materias: “…Publication of this special issue was made possible by AstraZeneca.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Clinical implications of the universal definition for the prevention and treatment of heart failure
  11. 231
    Materias: “…Publication of this special issue was made possible by AstraZeneca.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Evolving therapeutic strategies for patients hospitalized with new or worsening heart failure across the spectrum of left ventricular ejection fraction
  12. 232
    “…The following vaccines were reported; Gam-COVID-Vac (Sputnik V), ChAdOx1 nCoV-19 (AstraZeneca), BBV152 (Covaxin), or BBIBP-CorV (Sinopharm). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Vaccine-associated complications: a comparative multicenter evaluation among dental practitioners and dental students—which candidate vaccine is more safe in SARS COV II, Gam-COVID-Vac (Sputnik V), ChAdOx1 nCoV-19 (AstraZeneca), BBV152 (Covaxin), or BBIBP-CorV(Sinopharm)?
  13. 233
    Publicado 2013
    “…AstraZeneca Cardiovascular…”
    Electrónico Software eBook
    Asistente de imágenes : cardiología.
  14. 234
    Publicado 2013
    “…AstraZeneca Cardiovascular…”
    Electrónico Software eBook
    Asistente de imágenes : síndrome metabólico.
  15. 235
    Publicado 2010
    “…AstraZeneca. Cardiovascular…”
    Libro
    The year in hypertension : versión en español /
  16. 236
    “…DISCLOSURES: Joseph R Francica, PhD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Yingyun Cai, PhD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Seme Diallo, MS, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Kim Rosenthal, MS, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Kuishu Ren, BS, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Daniel J. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1355. The SARS-CoV-2 Monoclonal Antibody AZD3152 Potently Neutralizes Historical and Emerging Variants and is Being Developed for the Prevention and Treatment of COVID-19 in High-risk Individuals
  17. 237
    “…DISCLOSURES: Lindsay E. Clegg, PhD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Oleg Stepanov, MS, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Henning Schmidt, PhD, AstraZeneca: Employed by IntiQuan, which received payment from AstraZeneca for work involved in this analysis Ventakesh Pilla Reddy, PhD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Weifeng Tang, MD, PhD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Michael Gibbs, PhD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Sangeeta Sedani, MSc, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Antonella Nadia Tuillio, MD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Sam Sadow, MA, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Nuria Martinez-Alier, PhD, AstraZeneca: Employee|AstraZeneca: Employement|AstraZeneca: Stocks/Bonds|AstraZeneca: Stocks/Bonds Taylor Cohen, PhD, AstraZeneca: Employement|AstraZeneca: Stocks/Bonds Saul N. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    394. Consistency of AZD7442 (Cilgavimab/Tixagevimab) Pharmacokinetics Across Prophylaxis and Treatment and Adult and Pediatric Participants: Application of Population Pharmacokinetics to Enable Rapid Decision-Making During the COVID-19 Pandemic
  18. 238
    “…Tuffy, MS, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Hong Ji, BSc, AstraZeneca: Stocks/Bonds Christine Blaze, BSc, AstraZeneca: Stocks/Bonds Tyler Brady, MS, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Pamela Griffin, MD, AstraZeneca: Stocks/Bonds Amanda Leach, MD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Tonya L. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    94. Pooled analysis of nirsevimab resistance through 150 days post dose in preterm and term infants
  19. 239
    “…Near, MD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Katie Streicher, PhD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Alexandre Kiazand, MD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Mark T. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1353. Safety of AZD7442 (Tixagevimab/Cilgavimab) for Post-exposure Prophylaxis of COVID-19: Final Analysis of the STORM CHASER Phase 3 Study
  20. 240
    “…Esser, PhD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    529. Safety of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Phase 3 Study
Herramientas de búsqueda: RSS